Procarbazine hydrochloride is named as an intervention in 2 current clinical trials in our Egypt, Germany, France, Italy, Netherlands, Belgium, Poland, Portugal, Canada, Mexico and Israel registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is European Organisation for Research and Treatment of Cancer - EORTC (1). The most-studied condition is Lymphoma.
Of the three regulators tracked here, the first to approve Procarbazine hydrochloride was the US, on 22 Jul 1969.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1321, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 7278, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| National Cancer Institute (NCI) | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Egypt, Germany, France, Italy, Netherlands, Belgium, Poland, Portugal, Canada, Mexico and Israel registers name Procarbazine hydrochloride (also registered as Monohydrochloride (9CI)) as a drug or biological intervention, as of the registry sync on 2 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Egypt, 1 with sites in Canada, 1 with sites in Mexico and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
European Organisation for Research and Treatment of Cancer - EORTC (1) and National Cancer Institute (NCI) (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Procarbazine hydrochloride works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Procarbazine hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Procarbazine hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 2 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
